PMID- 26358006
OWN - NLM
STAT- MEDLINE
DCOM- 20160819
LR  - 20220330
IS  - 1744-8409 (Electronic)
IS  - 1744-666X (Linking)
VI  - 11
IP  - 12
DP  - 2015
TI  - From IgE to clinical trials of allergic rhinitis.
PG  - 1321-33
LID - 10.1586/1744666X.2015.1086645 [doi]
AB  - The current scientific research is continuously aiming at identifying new 
      therapeutic targets with the purpose of modifying the immune response to 
      allergens. The evolution in immunological methods has led to the identification 
      of immunoglobulin E (IgE) as both a diagnostic biomarker and potential 
      therapeutic target in allergic diseases, such as allergic rhinitis. Allergen 
      immunotherapy has been used for more than 100 years to treat allergic diseases 
      and it is today considered the only disease-modifying treatment capable of 
      inducing a long-lasting immunological and clinical tolerance toward the causal 
      allergen. During the past 20 years, major advances have been made in 
      understanding the molecular and cellular mechanisms of allergen tolerance in 
      humans. Moreover, there has been considerable progress in allergen extract 
      modifications and additions to standard extracts. The recognition that IgE plays 
      a pivotal role in basic regulatory mechanisms of allergic inflammation has 
      recently stimulated research into the therapeutic potential of directly targeting 
      this antibody. Omalizumab, the most advanced humanized anti-IgE monoclonal 
      antibody, is currently approved for the treatment of uncontrolled allergic asthma 
      and chronic spontaneous urticaria. Interesting results also arise from studies in 
      which omalizumab was administered in patients with allergic rhinitis. The aim of 
      this review is to provide an update on current findings on immunological and 
      clinical effects of allergen immunotherapy and anti-IgE therapy, which have been 
      shown to have synergistic modes of action for the treatment of allergic rhinitis.
FAU - Ciprandi, Giorgio
AU  - Ciprandi G
AD  - a 1 Department of Medicine, IRCCS-A.O.U. San Martino di Genova, Genoa, Italy.
FAU - Marseglia, Gian Luigi
AU  - Marseglia GL
AD  - b 2 Department of Pediatrics, Foundation IRCCS Policlinico San Matteo, University 
      of Pavia, Pavia, Italy.
FAU - Castagnoli, Riccardo
AU  - Castagnoli R
AD  - b 2 Department of Pediatrics, Foundation IRCCS Policlinico San Matteo, University 
      of Pavia, Pavia, Italy.
FAU - Valsecchi, Chiara
AU  - Valsecchi C
AD  - b 2 Department of Pediatrics, Foundation IRCCS Policlinico San Matteo, University 
      of Pavia, Pavia, Italy.
FAU - Tagliacarne, Carlotta
AU  - Tagliacarne C
AD  - b 2 Department of Pediatrics, Foundation IRCCS Policlinico San Matteo, University 
      of Pavia, Pavia, Italy.
FAU - Caimmi, Silvia
AU  - Caimmi S
AD  - b 2 Department of Pediatrics, Foundation IRCCS Policlinico San Matteo, University 
      of Pavia, Pavia, Italy.
FAU - Licari, Amelia
AU  - Licari A
AD  - b 2 Department of Pediatrics, Foundation IRCCS Policlinico San Matteo, University 
      of Pavia, Pavia, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150910
PL  - England
TA  - Expert Rev Clin Immunol
JT  - Expert review of clinical immunology
JID - 101271248
RN  - 0 (Allergens)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - *Allergens/chemistry/immunology/therapeutic use
MH  - *Desensitization, Immunologic
MH  - Humans
MH  - Immunoglobulin E/*immunology
MH  - Rhinitis, Allergic/*immunology/*therapy
OTO - NOTNLM
OT  - IgE
OT  - allergen immunotherapy
OT  - allergic rhinitis
OT  - omalizumab
OT  - sublingual immunotherapy
EDAT- 2015/09/12 06:00
MHDA- 2016/08/20 06:00
CRDT- 2015/09/12 06:00
PHST- 2015/09/12 06:00 [entrez]
PHST- 2015/09/12 06:00 [pubmed]
PHST- 2016/08/20 06:00 [medline]
AID - 10.1586/1744666X.2015.1086645 [doi]
PST - ppublish
SO  - Expert Rev Clin Immunol. 2015;11(12):1321-33. doi: 10.1586/1744666X.2015.1086645. 
      Epub 2015 Sep 10.